Compass Pathways is on track to complete its NDA filing for treatment-resistant depression by the end of the year despite a stock drop.
Kabir Nath, Compass Pathways CEO
July 7, 2026 11:27 AM EDT
Compass Pathways touts durability data for psilocybin drug in depression ahead of year-end filing
Ayisha Sharma
News Reporter
Compass Pathways reported positive 26-week Phase 3 COMP360 data for treatment-resistant depression as its FDA filing remains on…
This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, according…
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Compass Pathways Elects Kathleen Tregoning to Board of Directors
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the…
Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout
